本文關(guān)鍵詞： FSHR PLGA 納米疫苗 避孕　出處：《第三軍醫(yī)大學(xué)學(xué)報(bào)》2015年04期 　論文類型：期刊論文

【摘要】：目的構(gòu)建聚乳酸-羥乙酸共聚物(polylactic acid-glycolic acid,PLGA)包載促卵泡生成素受體表位肽(FSHR32-44)的納米粒,探討PLGA材料作為避孕疫苗載體的可行性。方法使用PLGA為載體,制備出包載促卵泡生成素受體的B細(xì)胞表位(FSHR32-44)的納米粒,透射電鏡(TEM)觀察表觀形態(tài),粒徑儀檢測(cè)粒徑分布范圍和Zeta電位,體外釋放試驗(yàn)檢測(cè)其理化特性。激光共聚焦顯微鏡觀察小鼠骨髓來源樹突狀細(xì)胞(DCs)吞噬FSHR可溶性多肽和FSHR/PLGA NP的能力,流式細(xì)胞儀檢測(cè)FSHR、PLGA NP和FSHR/PLGA NP促骨髓來源DCs成熟能力。結(jié)果單乳-溶劑揮發(fā)法制備的FSHR/PLGA NP大小粒徑分布均勻、表面規(guī)整,粒徑(296.3±3.5)nm,Zeta電位(-16.1±0.4)m V,FSHR包封率(62.71±2.83)%,并具有緩慢釋放抗原的能力;體外細(xì)胞水平實(shí)驗(yàn)結(jié)果顯示FSHR表位肽納米粒易于被DCs攝取,有劑量和時(shí)間依賴性,能顯著上調(diào)DCs表面CD40、CD86、CD83和MHC-Ⅱ功能分子的表達(dá)。結(jié)論 PLGA包載FSHR多肽有良好的包封率,易被DCs吞噬,并有強(qiáng)的促進(jìn)DCs成熟作用,可以作為FSHR32-44避孕疫苗的載體。
[Abstract]:Objective to construct the nanoparticles of poly (lactic acid) -glycolactic acid-glycolic acidoga (PLGA) coated with follicle stimulating hormone (FSHR32-44), and to explore the feasibility of using PLGA as a contraceptive vaccine carrier. Methods PLGA was used as the carrier. The B cell epitope (FSHR32-44) loaded with follicle stimulating hormone receptor (FSHR32-44) was prepared. The apparent morphology was observed by transmission electron microscopy (TEM). The particle size distribution and Zeta potential were measured by particle size analyzer. Laser confocal microscopy was used to observe the ability of murine bone marrow-derived dendritic cells to phagocytosis of FSHR soluble polypeptides and FSHR/PLGA NP. Results the size distribution of FSHR/PLGA NP prepared by single emulsion solvent volatilization method was uniform, the surface of FSHR/PLGA NP was regular, the encapsulation efficiency of FSHR/PLGA NP was 62.71 鹵2.83%, and the encapsulation efficiency of FSHR/PLGA NP was 62.71 鹵2.83%. The results of cell level assay in vitro showed that FSHR epitope peptide nanoparticles were easy to be ingested by DCs in a dose-and time-dependent manner, and could significantly up-regulate the expression of CD40, CD86, CD83 and MHC- 鈪，

本文編號(hào)：1554913